Xin Nakanishi
Directeur/Bestuurslid bij ONCTERNAL THERAPEUTICS, INC.
Vermogen: 858 $ op 30-04-2024
Profiel
Xin Nakanishi is the founder of Sunvita Therapeutics, LLC, which was founded in 2009.
She served as the Chief Executive Officer from 2009 to 2018.
Currently, she is the Chief Executive Officer at Shanghai Pharma Biotherapeutics Usa, Inc. and an Independent Director at Oncternal Therapeutics, Inc. She previously worked as the Biology Director at Phenomix Corp.
and Director at Oncternal Oncology, Inc. She also served as a Venture Partner at Yuansheng Bioventure, Inc. from 2017 to 2018.
Dr. Nakanishi received her undergraduate degree from Wuhan University and her doctorate from the University of Kansas.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
28-06-2023 | 104 ( 0.00% ) | 858 $ | 30-04-2024 |
Actieve functies van Xin Nakanishi
Bedrijven | Functie | Begin |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-11-2018 |
Shanghai Pharma Biotherapeutics Usa, Inc. | Algemeen Directeur | 01-07-2018 |
Eerdere bekende functies van Xin Nakanishi
Bedrijven | Functie | Einde |
---|---|---|
Sunvita Therapeutics, LLC | Algemeen Directeur | 01-01-2018 |
Yuansheng Bioventure, Inc. | Corporate Officer/Principal | 01-01-2018 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | - |
Oncternal Oncology, Inc.
Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Directeur/Bestuurslid | - |
Opleiding van Xin Nakanishi
Wuhan University | Undergraduate Degree |
University of Kansas | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Oncternal Oncology, Inc.
Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Health Technology |
Shanghai Pharma Biotherapeutics Usa, Inc. | |
Yuansheng Bioventure, Inc. | |
Sunvita Therapeutics, LLC |